BioRx Receives Limited Distribution Rights to Corifact for the Treatment of Congenital Factor XIII Deficiency
BioRx has been added to the limited distribution network for Corifact, the only FDA-approved treatment for congenital Factor XIII deficiency.
BioRx, a national specialty pharmacy and infusion services provider, has been added to the limited distribution network for Corifact [Factor XIII Concentrate (Human)], manufactured by CSL Behring. Corifact is the only FDA-approved treatment for congenital Factor XIII deficiency, reported to be one of the rarest bleeding disorders in the world. The drug was originally approved by the Food and Drug Administration in February 2011.
BioRx specializes in the home treatment of rare, orphan diseases. To date, Corifact has only been available through two specialty pharmacy providers. The addition of BioRx to the distribution channel gives patients and their treating physicians another choice.
"We are very excited to begin serving the factor XIII patient population," said Eric Hill, co-founder of BioRx. "We are also pleased to expand our distribution partnership with CSL Behring in the bleeding disorders market. Corifact is a perfect match for our service model due to the small population it treats."
BioRx has provided pharmacy and infusion services to patients with bleeding disorders since its founding in 2004 - primarily for patients with factor VIII or factor IX deficiency ("hemophilia A" and "hemophilia B" respectively). Unlike its competitors in the specialty pharmacy market, BioRx provides decentralized services that customize care for patients to help them better manage their bleeding disorder at home in a real-world environment. BioRx will apply a similar, personalized approach to the care of patients with factor XIII deficiency.
"Our goal is to be the first choice of prescribing physicians when they're looking for safe and effective treatment with Corifact," said Hill. "In dealing with rare diseases, it's often not enough to trust that a drug alone will achieve its expectations, and there are inevitable risks to products that require close observation and surveillance. With Corifact, we will provide intensive support for patients who, before Corifact's introduction, have been constrained by very limited treatment options."
BioRx began distributing Corifact on July 1, 2012.
About Factor XIII Deficiency
Factor XIII deficiency is characterized by absent or deficient levels of factor XIII clotting protein, resulting in unstable clot formation and delayed bleeding at the site of injury. As with both hemophilia A and B, symptoms can range from mild to moderate. Unlike hemophilia A and B, however, factor XIII deficiency is an autosomal recessive disorder that affects both males and females equally. It is also believed to be largely undiagnosed. Until the introduction of Corifact in the U.S., the only treatments available for factor XIII deficiency were fresh plasma and cryoprecipitate. Factor XIII deficiency affects approximately one in 2 million to one in 5 million people.
Based in Cincinnati, Ohio, BioRx is one of the nation's fastest growing providers of specialty pharmaceuticals and infusion services, delivering highly customized care for patients with certain rare and chronic diseases. In addition to serving the bleeding disorders community, BioRx offers pharmacy, nursing and education services to patients with hereditary angioedema, immune deficiencies, autoimmune disorders, alpha-1 antitrypsin deficiency, and nutritional/digestive disorders. The company's clinical staff reaches patients and physicians in all 50 states. To learn more about BioRx and its products and services, visit www.biorx.com .